RedHill Biopharma (RDHL) EBT Margin (2012 - 2023)
RedHill Biopharma (RDHL) posted quarterly EBT Margin of 3280.68% for Q2 2023, up 324467.0% year-over-year from N/an in Q2 2022, and up 1590.99% quarter-over-quarter from 220.03% in Q1 2023.
RedHill Biopharma (RDHL) EBT Margin (2012 - 2023) Analysis & Trends
RedHill Biopharma (RDHL) has reported EBT Margin for 12 consecutive years, with 3280.68% the latest figure, recorded in Q2 2023.
- In Q2 2023, EBT Margin rose 324467.0% year-over-year to 3280.68%; the TTM figure through Jun 2023 stood at 111.91% (up 3377.0% YoY), while the FY2025 annual figure was 150.0%, down 4720.0% from the prior year.
- EBT Margin rose to 3280.68% in Q2 2023 per RDHL's latest filing, from 220.03% in the prior quarter.
- Across five years, EBT Margin topped out at 3280.68% in Q2 2023 and bottomed at 644.28% in Q4 2021.
- Historically, EBT Margin has averaged 370.89% across 5 years, with a median of 63.69% in 2021.
- Annual changes were most pronounced in 2021 — EBT Margin plunged 149215 bps — and 2023, when it surged 324467 bps.
- RedHill Biopharma's EBT Margin stood at 744.47% in 2019, then tumbled by 93 bps to 49.09% in 2020, then sank by 1412 bps to 644.28% in 2021, then rose by 16 bps to 543.22% in 2022, then surged by 704 bps to 3280.68% in 2023.
- Business Quant data shows RDHL's EBT Margin at 3280.68% in Q2 2023, 220.03% in Q1 2023, and 543.22% in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -10.99% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 13.34% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 47.58% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.70% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 16.91% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 4.09% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | RedHill Biopharma | 2.05 Bn | 2.05 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 3,280.68% |
| Mar 31, 2023 | -220.03% |
| Dec 31, 2022 | -543.22% |
| Sep 30, 2022 | -122.41% |
| Jun 30, 2022 | 36.01% |
| Mar 31, 2022 | 97.15% |
| Dec 31, 2021 | -644.28% |
| Sep 30, 2021 | 62.05% |
| Jun 30, 2021 | 96.04% |
| Mar 31, 2021 | 65.33% |
| Dec 31, 2020 | 49.09% |
| Sep 30, 2020 | 49.10% |
| Jun 30, 2020 | 42.84% |
| Mar 31, 2020 | 1,557.48% |
| Dec 31, 2019 | 744.47% |
| Sep 30, 2019 | 729.48% |
| Jun 30, 2019 | 903.71% |
| Mar 31, 2019 | 492.57% |
| Dec 31, 2018 | 912.58% |
| Sep 30, 2018 | 425.61% |